Five-leaved Chaste Tree

Vitex negundo leaf extracts contain iridoid glycosides (notably agnuside at 3.04 ± 0.02% dry weight), flavonoids (isoorientin, isovitexin, scutellarin), and terpenoids (viridiflorol) that exert antioxidant activity via free radical scavenging and hydrogen bond-mediated enzyme inhibition. Preclinical murine models demonstrate significant anti-inflammatory efficacy at 9.6–28.8 g/kg leaf weight equivalents, with outcomes comparable to methylprednisolone (10 mg/kg), though no controlled human clinical trials have yet confirmed these effects.

Origin & History

Vitex negundo is native to tropical and subtropical Asia, distributed across India, Sri Lanka, China, the Philippines, and East Africa, typically growing in scrublands, riverbanks, and forest margins at altitudes up to 1,500 meters. The plant thrives in well-drained loamy soils under full sun and is cultivated as a perennial shrub reaching 2–5 meters in height. Historically, it has been extensively harvested from wild populations across the Indian subcontinent for Ayurvedic and Traditional Chinese Medicine (TCM) applications, with leaves, roots, and seeds all used medicinally.

Historical & Cultural Context

Vitex negundo has been documented in Ayurvedic texts including the Charaka Samhita and Sushruta Samhita under the Sanskrit name 'Nirgundi,' where it is classified as a bitter, pungent, and astringent herb with hot potency (Ushna Veerya) prescribed for fever, rheumatic pain, elephantiasis, and worm infestations. In Traditional Chinese Medicine, it is referenced as 'Huang Jing Zi' and used for wind-damp painful obstruction, headache, and eye disorders. Across Southeast Asia, leaves are traditionally smoked or used as fumigants against insects, and fresh leaf poultices are applied to arthritic joints, bruises, and sprains in folk medicine from the Philippines, Sri Lanka, and Indonesia. Colonial-era botanical surveys by British naturalists in India (18th–19th centuries) documented its widespread medicinal use, and it remains an officially recognized plant in the Ayurvedic Pharmacopoeia of India.

Health Benefits

- **Antioxidant Activity**: Flavonoids including isoorientin, isovitexin, and scutellarin scavenge reactive oxygen species (ROS) through electron donation; quantified antioxidant fractions show dose-dependent radical quenching in LC-ECD assays calibrated at 0.25–50 µg/mL (R²=0.9993).
- **Anti-inflammatory Effects**: Methanolic leaf extracts at 9.6 g/kg and 28.8 g/kg (mouse body weight) significantly reduced chronic peritoneal inflammation to levels comparable to the corticosteroid methylprednisolone (10 mg/kg), suggesting potent prostaglandin or cytokine pathway modulation.
- **Analgesic Properties**: Traditional Ayurvedic use and preclinical data support pain-relieving effects attributed to agnuside and terpenoid constituents, likely through inhibition of COX-mediated nociceptive pathways, though specific IC50 values for pain endpoints in mammalian models are not yet fully characterized.
- **Prolactin-Lowering (Hyperprolactinemia Relief)**: Octadecadienoic acid and terpenoids within V. negundo extracts have been associated with serum prolactin reduction, offering a mechanistic basis for their traditional use in mastodynia (breast pain) and menstrual irregularities linked to elevated prolactin.
- **Antimicrobial Activity**: GC-MS-identified constituents including hexadecanoic acid methyl ester and viridiflorol demonstrate inhibitory activity against Mycobacterium tuberculosis and other pathogens, positioning the plant as a candidate adjunct in infectious disease research.
- **Anti-tumor Potential**: Phenolic acids (2.70 mg/g dried extract) and phytosterols (1.1 mg/g) contribute to cytostatic and pro-apoptotic effects observed in cell-line studies, attributed to disruption of redox homeostasis in rapidly proliferating cells.
- **Antipyretic and Anthelmintic Effects**: Bitter and pungent leaf constituents including oleanolic acid, sitosterol, negundoside, and vetugnoside have been documented in Ayurvedic texts and corroborated by preclinical data as contributing to fever reduction and intestinal parasite clearance.

How It Works

Agnuside, the principal iridoid glucoside quantified at 3.04 ± 0.02% in dried V. negundo leaves, exhibits strong antioxidant and anti-inflammatory activity via formation of up to 11 hydrogen bonds with topoisomerase enzyme residues alongside Amide-Pi Stacked and Pi-Alkyl interactions (in silico docking scores >100), effectively competing with endogenous substrates at catalytic sites. Flavonoids such as isoorientin and scutellarin donate hydrogen atoms to neutralize peroxyl and hydroxyl radicals, reducing lipid peroxidation cascades and attenuating NF-κB-dependent pro-inflammatory cytokine transcription. Octadecadienoic acid (a polyunsaturated fatty acid comprising 21.93% of wild-leaf GC-MS fractions) and the sesquiterpenoid viridiflorol modulate arachidonic acid metabolism, reducing downstream prostaglandin E2 synthesis and suppressing serum prolactin through dopaminergic receptor pathway interactions. Phenolic acids and phytosterols (sitosterol, oleanolic acid) contribute additional membrane-stabilizing and enzyme-inhibitory effects that collectively account for the broad-spectrum pharmacological activity observed in preclinical models.

Scientific Research

The existing evidence base for Vitex negundo is almost entirely preclinical, comprising in vitro assays and rodent (murine) models, with no published randomized controlled human clinical trials identified in the peer-reviewed literature to date. Key preclinical findings include significant chronic anti-inflammatory activity in mouse peritoneal models at oral doses of 9.6 g/kg and 28.8 g/kg leaf equivalents, benchmarked against methylprednisolone (10 mg/kg), and quantitative phytochemical profiling via validated HPLC (R²=0.9999, RSD ≤2.50%) and GC-MS methods identifying 24 bioactive compounds. In vitro callus induction studies demonstrated that white and green callus cultures produce 40.38% and 47.79% octadecadienoic acid respectively—nearly double the 21.93% found in wild leaves—suggesting biotechnological strategies for producing concentrated bioactive material. The overall evidence quality is limited (evidence score 4/10), and extrapolation of preclinical dose–response data to human therapeutic windows requires significant caution and formal phase I/II clinical investigation.

Clinical Summary

No registered human clinical trials with defined endpoints, sample sizes, or statistically reported effect sizes have been published for Vitex negundo extracts or its isolated compounds (agnuside, isoorientin, octadecadienoic acid) as of available literature. Animal model data in mice provide a preliminary signal for anti-inflammatory efficacy comparable to corticosteroid reference drugs at high oral doses (9.6–28.8 g/kg), but allometric scaling to human equivalents yields dose estimates that require formal safety and pharmacokinetic characterization before clinical use. Traditional use across centuries in Ayurveda and TCM for fever, pain, mastodynia, and inflammation represents ethnopharmacological evidence of efficacy, though this does not substitute for controlled clinical outcome data. Confidence in translational benefit remains low-to-moderate pending well-designed phase I dose-escalation and phase II efficacy trials in human populations.

Nutritional Profile

Vitex negundo leaves contain a complex phytochemical matrix rather than a conventional macronutrient profile. Key constituents include phenolic acids at approximately 2.70 mg/g dried leaf, phytosterols (primarily sitosterol and oleanolic acid) at 1.1 mg/g, and total lipids at approximately 0.5% w/w dominated by octadecadienoic acid (linoleic acid, 21.93% of GC-MS fraction in wild leaf). Iridoid glycosides including agnuside are present at 3.04 ± 0.02% by HPLC dry weight, representing the principal standardizable marker compound. Flavonoids—isoorientin, isovitexin, scutellarin, cynaroside, and chlorogenic acid—contribute to total polyphenol content, though aggregate polyphenol quantification across standardized extraction methods has not been uniformly reported. Bioavailability of agnuside and flavonoid glycosides is expected to be influenced by intestinal glucosidase activity and first-pass hepatic metabolism, with aglycone forms likely exhibiting greater membrane permeability, though formal human pharmacokinetic data are absent.

Preparation & Dosage

- **Traditional Aqueous/Methanolic Leaf Extract**: Prepared by cold maceration or Soxhlet extraction of dried leaves in 70–100% methanol; used experimentally at 9.6–28.8 g/kg in mice (human equivalent dose not established).
- **Dried Leaf Powder**: Traditionally consumed at 3–6 g/day in Ayurvedic formulations, though no pharmacopoeial standardization exists for V. negundo leaf powder in Western regulatory frameworks.
- **Standardized Agnuside Extract**: Research-grade HPLC-standardized extracts contain 3.04 ± 0.02% agnuside by dry weight; no commercial supplement standardization has been formally established.
- **Decoction (Traditional TCM/Ayurveda)**: Leaves boiled in water (10–20 g dried leaf per 500 mL) for 15–20 minutes; filtered and consumed as a tea for analgesic and antipyretic effects.
- **Callus-Derived Concentrate (Experimental)**: In vitro callus cultures on Murashige-Skoog (MS) medium with 2.0 mg/L BAP and 0.2 mg/L 2,4-D yield extracts with up to 47.79% octadecadienoic acid; not available commercially.
- **Topical Leaf Paste**: Fresh leaves ground and applied directly to joints or inflamed areas in traditional practice; no standardized formulation or validated clinical dose exists.
- **Timing Note**: Anti-inflammatory and antioxidant effects in preclinical models are assessed after repeated dosing over days to weeks; single-dose kinetics in humans are unknown.

Synergy & Pairings

Vitex negundo extracts may exhibit additive or synergistic antioxidant effects when combined with Withania somnifera (ashwagandha), as withanolides complement iridoid glycoside-mediated NF-κB suppression through independent MAPK pathway modulation, potentially broadening the anti-inflammatory coverage. Co-administration with curcumin (from Curcuma longa) is theoretically synergistic given complementary COX-2 inhibition by curcuminoids and prostaglandin pathway modulation by V. negundo terpenoids, a pairing commonly employed in Ayurvedic compound formulations (Rasayanas). The flavonoid fraction of V. negundo (isoorientin, scutellarin) may also potentiate the bioavailability of lipophilic phytosterols such as sitosterol through mixed micellar formation in the gastrointestinal tract, though this mechanism has not been formally validated for this specific plant.

Safety & Interactions

Formal human safety data for Vitex negundo extracts are not available, as no phase I clinical trials have been published; preclinical murine studies at doses up to 28.8 g/kg leaf weight equivalent did not report acute toxicity, suggesting a broad safety margin in animal models, but this cannot be directly extrapolated to humans. The prolactin-lowering activity attributed to dopaminergic constituents raises a theoretical concern for interaction with dopamine antagonist medications (e.g., antipsychotics such as haloperidol, metoclopramide) and hormone-sensitive conditions. Pregnancy and lactation use is contraindicated based on traditional advisory caution and the plant's documented hormonal (prolactin-lowering) and uterine-stimulating properties noted in ethnomedicinal texts; no controlled reproductive toxicity studies have been conducted. Individuals with hypersensitivity to Lamiaceae (mint family) plants should exercise caution, and concurrent use with immunosuppressants or anti-inflammatory medications warrants medical supervision given the potential for pharmacodynamic additive effects.